Abstract:Osteoarthritis (OA) is the most common inflammatory joint disease and currently lacks an effective curative treatment. Intra-articular injection of mesenchymal stromal cells (MSCs) has gained attention as a relevant therapeutic approach for OA treatment due to the MSC’s ability to secrete anti-inflammatory and immunomodulatory factors. Given their limited viability post- intraarticular injection and the potential leakage of cells out of the injection site, encapsulating MSCs in hydrogels is considered a promising strategy to protect them and provide a suitable 3D microenvironment to support their biological activities. Calcium-cross-linked alginate hydrogels are commonly used for MSC encapsulation, but their long-term in vivo stability remains uncertain. On the other hand, alginate cross-linking by the strain-promoted azide- alkyne cycloaddition (SPAAC) reaction would create a network unaffected by an ionic environment. Hence, this study aimed to develop an alginate-based hydrogel cross-linked via stable and cytocompatible covalent bonds for cell encapsulation. We established for the first time the formation of covalent alginate hydrogels between two SPAAC precursors, namely alginate-BCN and alginate-N . These hydrogels exhibited in vitro stability and enabled the diffusion of molecules of interest. We then generated alginate-based SPAAC microgels of 170 μm in mean diameter, suitable for intra-articular injection. We next encapsulated human adipose MSCs (hASCs) in these alginate-based SPAAC microgels and confirmed their cytocompatibility, with over 90 % of cells remaining viable after 14 days in culture. Finally, the microencapsulated hASCs maintained their biological properties and were able to secrete anti-inflammatory factors (IDO, PGE2, and HGF) when exposed to pro-inflammatory cytokines (TNF-α and IFN-γ). In the end, human-activated lymphocytes were cultured in contact with microencapsulated hASCs, and CD3+ T cell proliferation was quantified by flow cytometry. We demonstrated that the encapsulation process did not impair the hASC immunomodulatory activity. Overall, our findings show the potential of alginate-based SPAAC hydrogels for microencapsulating hASCs for cell therapy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to improve the effectiveness and safety of cell therapy through microencapsulated mesenchymal stromal cells (MSCs) in the treatment of osteoarthritis (OA). Specifically, the researchers focus on how to encapsulate MSCs using covalent alginate hydrogels to solve problems such as low cell survival rate and easy leakage from the injection site in traditional methods. ### Background and Objectives of the Paper 1. **Current Situation of Osteoarthritis (OA)**: - Osteoarthritis is the most common inflammatory joint disease, and there is currently a lack of effective radical treatment methods. - Mesenchymal stromal cells (MSCs) are used in OA treatment because they can secrete anti - inflammatory and immunomodulatory factors, but their survival time and ability to maintain function in the joint are limited. 2. **Existing Challenges**: - MSCs have a short survival time after intra - articular injection. - Cells may leak from the injection site, affecting the treatment effect. - The existing calcium - ion - cross - linked alginate hydrogels have poor long - term stability in vivo. 3. **Research Objectives**: - Develop an alginate - based covalent cross - linked hydrogel to achieve stable and cell - compatible cross - linking through strain - promoted azide - alkyne cycloaddition (SPAAC). - Evaluate the encapsulation effect of this new type of hydrogel on MSCs, including cell survival rate, biological activity, and immunomodulatory function. ### Main Research Contents 1. **Synthesis and Characterization of Hydrogel**: - Synthesize two precursors, alginate - BCN and alginate - N3, by a one - step method. - Mix these two precursor solutions to form a covalent cross - linked alginate hydrogel. - Evaluate the gelation time and mechanical properties of the hydrogel through rheological tests. 2. **Diffusion Properties of Hydrogel**: - Test the diffusion of different molecules (such as fluorescein, FITC - labeled BSA, TNF - α, and IFN - γ) in the hydrogel. 3. **Microencapsulation of MSCs**: - Use micromolding technology to prepare microgels with a diameter of approximately 170 μm. - Encapsulate human adipose - derived mesenchymal stromal cells (hASCs) in these microgels and evaluate the cell survival rate and metabolic activity. 4. **Biological Activity Evaluation**: - Detect the secretory function of microencapsulated hASCs under inflammatory stimulation, including the secretion of anti - inflammatory factors such as IDO, PGE2, and HGF. - Evaluate the immunomodulatory function of microencapsulated hASCs by co - culturing with activated lymphocytes. ### Conclusion This study successfully developed a covalent cross - linked alginate hydrogel, which can effectively encapsulate hASCs and maintain their biological activity and immunomodulatory function. This new type of hydrogel shows good stability and cell compatibility in vitro, providing a new strategy for cell therapy of osteoarthritis.

Microencapsulation of mesenchymal stromal cells in covalent alginate hydrogels for cell therapy

Allogeneic Primary Mesenchymal Stem/stromal Cell Aggregates Within Poly(n-Isopropylacrylamide-co-acrylic Acid) Hydrogel for Osteochondral Regeneration

Probing the effects of polysaccharide hydrogel composition on the viability and pro-angiogenic function of human adipose-derived stromal cells

Probing the effects of polysaccharide hydrogel composition on the viability and pro‐angiogenic function of human adipose‐derived stromal cells

Encapsulation of Human-Bone-Marrow-Derived Mesenchymal Stem Cells in Small Alginate Beads Using One-Step Emulsification by Internal Gelation: In Vitro, and In Vivo Evaluation in Degenerate Intervertebral Disc Model

Encapsulated mesenchymal stromal cells for in vivo transplantation

A novel, microfluidic high-throughput single-cell encapsulation of human bone marrow mesenchymal stromal cells

Effects of Alginate Encapsulation on the Vertebral Bone Adherent Mesenchymal Stromal Cell Paracrine Secretome

Using Glucosamine to Improve the Properties of Photocrosslinked Gelatin Scaffolds

Controlled-Release Hydrogel Microspheres to Deliver Multipotent Stem Cells for Treatment of Knee Osteoarthritis

Microfluidic Encapsulation of Single Cells by Alginate Microgels Using a Trigger-Gellified Strategy.

Anti-Inflammatory Effects of Encapsulated Human Mesenchymal Stromal/Stem Cells and a Method to Scale-Up Cell Encapsulation

Regulation of the Stem Cell–Host Immune System Interplay Using Hydrogel Coencapsulation System with an Anti‐Inflammatory Drug

Continuous Microfluidic Encapsulation of Single Mesenchymal Stem Cells Using Alginate Microgels as Injectable Fillers for Bone Regeneration

Enhanced osteogenesis of mesenchymal stem cells encapsulated in injectable microporous hydrogel

Bone-derived MSCs encapsulated in alginate hydrogel prevent collagen-induced arthritis in mice through the activation of adenosine A2A/2B receptors in tolerogenic dendritic cells

Localized Hydrogel Microspheres for Osteoarthritis Treatment: Recruitment and Differentiation of Stem Cells

Encapsulated Dental-Derived Mesenchymal Stem Cells in an Injectable and Biodegradable Scaffold for Applications in Bone Tissue Engineering.

Dental Mesenchymal Stem Cells Encapsulated in an Alginate Hydrogel Co-Delivery Microencapsulation System for Cartilage Regeneration.

Hyaluronan-based hydrogel delivering glucose to mesenchymal stem cells intended to treat osteoarthritis

Injectable Microcryogels Reinforced Alginate Encapsulation of Mesenchymal Stromal Cells for Leak-Proof Delivery and Alleviation of Canine Disc Degeneration.